GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a

For generations, treating cancer has relied on a pretty brutal calculus: hit the body hard and hope the cancer dies first. Traditional chemotherapy is essentially a scorched-earth strategy. It works, but at a massive cost—wrecking the heart, gut, and nervous system along with the tumour. . For decades, researchers have chased a deceptively simple question: What if we could send the drug only where it’s actually needed? Antibody-drug conjugates, or ADCs, are the most promising